{
  "nct_id": "NCT65859436",
  "indication": "Rheumatoid Arthritis",
  "phase": "Phase 2",
  "sample_size": 135,
  "duration_weeks": 26,
  "dropout_rate": 0.17,
  "blinding": "double-blind",
  "control_arm": "standard of care",
  "primary_endpoints": [
    "HAQ-DI improvement"
  ],
  "secondary_endpoints": [
    "DAS28 score reduction",
    "ACR20 response"
  ],
  "outcome_summary": "Statistically significant clinical benefit observed",
  "success": 1,
  "start_date": "2023-09-05",
  "completion_date": "2024-03-05"
}